tbuckley/cabot-search huggingface dataset:
Abstract 4371: Optimal drug concentration screening and evaluation in cancer stem cells &amp; 3D tumor stem cell cultures drug response assays in association with clinical efficacy for melanoma cancer stem cell
Authors: Jenna Passarini, John Patrick Cleary, Preetham Kumar, Trisha Newton, Sharmila Shankar, Cristian Sharma, Michael Sharma, Rubio R. Punzalan, Bhuvesh K. Sharma, Sherven Sharma, Parkash Gill, Rakesh K. Srivastava, Jay P. Sharma
Journal: Cancer Research (2011)

Abstract Optimal drug concentration screening and evaluation in Cancer stem cells &amp; 3D Tumor Stem Cell cultures Drug Response assays in association with Clinical efficacy for Melanoma Cancer Stem Cell. Three-dimensional (3D) culture of cancer cell lines has long been advocated as a better model of the malignant phenotype that is most closely related to tumorigenicity in vivo. Moreover, new drug development requires simple in vitro models that resemble the in vivo situation more in order to select active drugs against solid tumors and to decrease the use of experimental animals. The induction of chemotherapy or concomitant chemoradiotherapy has been used to increasingly to improve survival, and organ preservation. This approach encounters significant morbidity and mortality. Therefore reliable chemosensitivity assays are needed to accurately predict the response to chemotherapy and guide the selection and treatment of cancer patients. The purpose of this study is to examine and evaluate optimum drug candidates in vitro chemosensitivity on patient tumor tissues directly in culture and on their Cancer stem cell cultures. The tumor samples obtained after surgery or biopsy, were placed immediately in Celprogen Tumor Transportation Media and shipped at 4-8 OC for processing. Tissues were washed with 1X PBS solution and aseptically cut into 0.5mm sections and cultured in 6 well tissue culture plates with an insert pre-coated with ECM. All cancer cell types remain viable and maintain their native architecture for at least 14 days and incorporated DNA measured by adding EdU(5-ethynyl-2’-deoxyuridine) to the culture. The efficacy of various therapeutic agents targeting major pathways (wnt, Notch, PI3K, MAPK, STAT) and chemotherapy agents were tested using DNA uptake and TUNNEL assay anti-cancer agents was calculated according to the inhibition index. The same compounds were tested for utilizing the patient's Melanoma Cancer stem Cell Cultures established with Celprogen's Media and ECM. Among the 300 compounds tested Adria, Taxol, DTIC, Thalidomide, Paclitaxel, Abraxane, Ertibux and Velcade were not effective against Melanoma Cancer Stem cell (CSC). We were able to show 3 compounds that were effective against Melanoma CSC targeting selected pathways. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4371. doi:10.1158/1538-7445.AM2011-4371
Dr Whom
Authors: William T. Rumage
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The BOOKS section of<i>JAMA</i>, Jan 25, 1985, contained a book review by Elliott B. Oppenheim.<sup>1</sup>He was commenting on the book by Sharon Room entitled<i>The Unwelcome Intruder: Freud's Struggle With Cancer</i>. I was disappointed and surprised to see the sentence "Who did Freud select to operate? I think the correct pronoun there is "whom."
The hepatocyte growth factor regulates the synthesis of acute-phase proteins in human hepatocytes: Divergent effect on interleukin-6-stimulated genes
Authors: M Guillen
Journal: Hepatology (1996)

Our study addressed the role of the human hepatocyte growth factor (HGF), a potent mitogen for mature rat and human hepatocytes, in the regulation of specific hepatic genes. The experimental evidence obtained in primary cultured human hepatocytes indicates that HGF regulates the synthesis of plasma proteins in a dose-response fashion. It stimulates the synthesis of the negative acute-phase proteins albumin, transferrin, and fibronectin, decreases that of alpha1-antichymotrypsin (ACT) and haptoglobin, and stimulates that of alpha2-macroglobulin (AMG), which in man is insensitive to inflammatory mediators. HGF had no effect on C-reactive protein (CRP) synthesis. These effects differ from those elicited by interleukin-6 (IL-6). The effects of HGF on fibrinogen and alpha1-antitrypsin were, however, similar to those induced by IL-6. The effects of HGF were also observed at the messenger RNA (mRNA) level. Time-course induction experiments showed that the effects of HGF on protein synthesis were delayed by about 48 to 72 hours, in contrast with the 12-hour lag found after IL-6 stimulation. Although the presence of glucocorticoids was not absolutely necessary for HGF to affect plasma protein synthesis, it moderately extended the effects. In pulse-chase experiments, it was found that the action of HGF was not due to an alteration of the rate of secretion of the proteins. The effects of HGF on the synthesis of albumin, transferrin, fibronectin, alpha1-antichymotrypsin, and haptoglobin could be counteracted by the simultaneous presence of IL-6 in the incubation media. A clear additive effect was observed only in the case of fibrinogen. No interaction was observed in the cases of CRP and AMG. The results of this study indicate that the effects of HGF on human hepatocytes may not simply be limited to its mitogenic activity, but that it also regulates hepatic-specific genes and antagonizes, in part, the action of IL-6.
What's new in the other general journals
Authors: Christopher Martyn
Journal: BMJ (2005)

Patients who survive an episode of venous thromboembolism are at risk of a recurrence, which is why they are usually treated with warfarin. But how long should this treatment continue? Randomised controlled trials investigating the impact of different durations of anticoagulation have reported conflicting results. A meta-analysis helps to resolve the discrepancies, but there is probably no straightforward answer. Fifteen randomised controlled trials evaluating different durations of anticoagulation in terms of risk of recurrence were included in the meta-analysis. The investigators found that the discordance between trials that reported large benefits and others that reported only small or no benefit was largely explained by differences in the periods used for defining recurrence rates. Differences in the baseline prevalence of risk factors accounted for much of the variation in event rates between studies. The investigators conclude that long term anticoagulation in patients with venous thromboembolism does reduce the risk of recurrence. The magnitude of this risk reduction is greatest while the patient is receiving treatment, but even after treatment is stopped there is benefit. The incremental benefit of prolonging anticoagulation decreases as the duration of anticoagulation increases but lasts for at least six months. JAMA 2005; 294: 706–15 [OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4] Pulmonary artery catheters have been used for 30 years to monitor cardiac output and other haemodynamic variables in severely ill patients. Although they are ingenious pieces of technology, argument continues over whether the quality of the information they provide outweighs the complications associated with their insertion. A randomised trial involving over 1000 patients from 65 intensive care units in the UK reports no difference in mortality or length of stay in hospital between patients managed with or without a catheter. Credit: LANCET The trial was pragmatic in its approach. Clinicians enrolled patients who they thought should be managed with a pulmonary artery catheter but, after randomisation, other … [1]: {openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.issn%253D0002-9955%26rft.aulast%253DOst%26rft.auinit1%253DD.%26rft.volume%253D294%26rft.issue%253D6%26rft.spage%253D706%26rft.epage%253D715%26rft.atitle%253DDuration%2Bof%2BAnticoagulation%2BFollowing%2BVenous%2BThromboembolism%253A%2BA%2BMeta-analysis%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.294.6.706%26rft_id%253Dinfo%253Apmid%252F16091573%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx [2]: /lookup/external-ref?access_num=10.1001/jama.294.6.706&link_type=DOI [3]: /lookup/external-ref?access_num=16091573&link_type=MED&atom=%2Fbmj%2F331%2F7514%2F423.atom [4]: /lookup/external-ref?access_num=000231068600024&link_type=ISI
New focus placed on von Willebrand disease
Authors: R. Voelker
Journal: JAMA (1997)

FOR MANY patients, the heavy menstrual periods, frequent nosebleeds, and ease in bruising seem normal. They likely have a sister or mother who also has heavy periods. Or a father or brother with nosebleeds or bleeding gums. "Because others in the family have it, they just think this is life," said Anne Dilley, PhD, an epidemiologist in the Hematologic Diseases Branch of the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. Dilley is among a group of researchers, clinicians, and advocates who want to assure patients that excessive bleeding and bruising don't have to be a way of life. They're trying to focus more attention on the often unrecognized von Willebrand disease, an autosomal disorder characterized by mucous membrane bleeding. As Dilley embarks on the last phase of the first large-scale epidemiologic study examining the prevalence of the bleeding disorder in women, the Food and Drug Administration (FDA)
Role of Genetic Polymorphism Peroxisome Proliferator-Activated Receptor- 2 Pro12Ala on Ethnic Susceptibility to Diabetes in South-Asian and Caucasian Subjects: Evidence for heterogeneity
Authors: V. Radha
Journal: Diabetes Care (2006)

OBJECTIVE—To determine whether the peroxisome proliferator–activated receptor (PPAR)-γ Pro12ala polymorphism modulates susceptibility to diabetes in South Asians.
Dermatology
Authors: Robert S. Stern
Journal: JAMA (1984)

In the past two years, the benefits and risks of a number of potent therapies used to treat common dermatologic conditions have become better defined. These treatments include the use of retinoids, phototherapy and photochemotherapy, prostaglandin inhibitors, ketoconazole, and lasers. In the laboratory, the relation of alterations of immune function to a variety of dermatologic diseases has been clarified. Investigations of the effects of UV radiation on the immune system have provided us with new perspectives about the role of sunlight in the etiology of melanoma and nonmelanoma skin cancer. There is an increased appreciation of the importance of precursor lesions for the development of melanoma, which can occur sporadically or as part of a familial syndrome known as the "dysplastic The nevus syndrome." The retinoids are molecules consisting of vitamin A and its synthetic analogs. They affect keratinization and sebaceous gland activity and may have anticancer activity.<sup>1</sup>They
ANTIVIVISECTIONISTS SEEK TO CRIPPLE NATION'S DEFENSE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Of Physician Assistants
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
α–Intercalated cells defend the urinary system from bacterial infection
Authors: Neal Paragas, Ritwij Kulkarni, Max Werth, Kai M. Schmidt-Ott, Catherine Forster, Rong Deng, Qingyin Zhang, Eugenia Singer, Alexander D. Klose, Tian Huai Shen, Kevin P. Francis, Sunetra Ray, Soundarapandian Vijayakumar, Samuel Seward, Mary E. Bovino, Katherine Xu, Yared Takabe, Fábio E. Amaral, Sumit Mohan, Rebecca Wax, Kaitlyn Corbin, Simone Sanna-Cherchi, Kiyoshi Mori, Lynne Johnson, Thomas Nickolas, Vivette D’Agati, Chyuan-Sheng Lin, Andong Qiu, Qais Al-Awqati, Adam J. Ratner, Jonathan Barasch
Journal: Journal of Clinical Investigation (2014)

The JCI, with the agreement of the corresponding authors and coauthors, is retracting the article "Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients."The IP: streptavidin/IB: anti-HDAC2 immunoblot panel in Figure 3B was recently identified as an inverted image of the right four lanes of the anti-H4 acetyl CHIP gel presented in Figure 2A.Additionally, the IP: anti-streptavidin/IB: anti-DDK immunoblot presented in Supplemental Figure 3A was identified as an inverted image of the left four lanes of the anti-H4 acetyl CHIP gel presented in Figure 2A.Further, in Figure 9B, the incorrect anti-HDAC2 immuno blot was presented.
General Surgery
Authors: Arthur E. Baue
Journal: JAMA (1986)

General surgery should be defined as that operative discipline in which surgeons take care of and supervise the care of patients with multiple systems injuries, diseases of the gastrointestinal tract and endocrine glands, and hernias. The training of general surgeons is broad enough to include the care of patients in need of endoscopy, intensive care, and support of the circulation and lungs and the capability of helping the subspecialist with general surgical care. In this brief essay, I will consider several important areas of recent advancement: shorter hospitalizations for surgical patients, ambulatory surgery, lesser operations for breast cancer, the possibility of fewer operations for gallstones, and centralized care of the injured. These important developments will not increase the work load or require a larger number of general surgeons. A recent study<sup>1</sup>of the years 1979 to 1984 indicated that the number of general surgical operations increased much less than
In Reply:
Authors: F. Andre, S. Delaloge, M. Spielmann
Journal: Journal of Clinical Oncology (2005)

Considering the results of three French cancer centers described in the study of Andre et al, 1 remarkable progress has been made in the treatment of breast cancer patients with synchronous metastases between 1987 and 2000.The 3-year overall survival rates of the patients improved from 27% to 44%, and the median survival increased from 23 to 29 months.In the Discussion of their article, the authors attribute part of the improvement to the increased use of taxanes and aromatase inhibitors.Although they recognize the limitations of their study design to make such a causal connection, some other potential confounders remain underexposed.From the Tables and the information in the Patients and Methods section, it is not clear whether all patients with metastatic disease have been included and if all patients have been seen by medical oncologists and have received systemic treatment.Data from the Eindhoven Cancer Registry in the Netherlands and clinical experience suggest that there will always be some patients with metastatic breast cancer who refuse systemic treatment or who are not referred to a medical oncologist because of serious comorbid conditions or an extremely short life expectancy.According to the data of the Eindhoven Cancer Registry, at least 6% of the patients with primary metastatic breast cancer diagnosed in the period from 1995 to 1997, did not receive systemic treatment; some of them received no treatment at all or only locoregional treatment, and others underwent nonsystemic palliative treatment such as radiotherapy for painful bone metastases or pleurodesis for malignant pleural effusions. 2What proportion of the patients in the study of Andre et al received no systemic treatment, and did it change over time?Exclusion of such patients from the analyses would overestimate the median and overall survival rates.Another possible source of bias that was not discussed is lead-time bias.The authors state that staging procedures for primary breast cancer were similar from 1987 to 2000, including physical examination, blood tests, chest x-ray, liver ultrasound, and bone scan.However, in many countries, the growing use of mammography during the 1980s and the introduction of breast cancer screening programs in the 1990s have led to the diagnosis of breast cancer tumors in an earlier stage.An earlier detection of the primary tumor may have led to earlier detection of metastatic disease and a better overall survival.To confirm this hypothesis, one would expect a decrease in the proportion of patients with metastatic disease in the presence of a large primary tumor and/or locally advanced breast cancer.To rule out the effect of lead-time bias, it might be necessary to adjust for changes in the local and regional tumor stage.
Comparative Single-Institute Analysis of Cord Blood Transplantation From Unrelated Donors with Related Bone Marrow or Peripheral Blood Stem-Cell Transplants in Elderly Patients with Hematologic Diseases After Reduced Intensity-Conditioning Regimen.
Authors: Naoyuki Uchida, Aya Nishida, Hiroshi Shimazu, Nobuaki Nakano, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Yuki Asano-Mori, Kazuhiro Masuoka, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2009)
Recherches Cliniques et Therapeutiques sur L'Epilepsie L'Hysterie. et L'Idiote. Compte-Rendu Service des Enfants Idiots. Epilleptiques et Arriérés de Bicétre Pendant L'Année, 1903.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Peritoneal Dialysis
Authors: John H. Samson
Journal: JAMA (1965)

<h3>To the Editor:—</h3> The article on peritoneal dialysis by Loeser et al (<i>JAMA</i><b>192</b>:809-812 [May 31] 1965) made one comment which is not only unclear but could prove dangerous. In one place the author states that deep coma with areflexia, shock, or apnea is an indication for dialysis. He gives several examples of drug intoxication effectively treated with dialysis. He fails to mention, however, that not all drugs are dialyzable; a good example is the phenothiazines. With certain drugs, the renal route of excretion with hydration and osmotic diuresis with mannitol has proved even more effective in eliminating the offending agent than has dialysis. This may be the case with barbiturates. Aspirin is an example of a drug more effectively cleared by urinary excretion than by dialysis. Other serious intoxicants which do not cause central nervous system depression are not effectively cleared by peritoneal dialysis; digoxin (Lanoxin) is a
Principles and Practice of Biological Assay
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erythropoiesis
Authors: Frederick Stohlman
Journal: New England Journal of Medicine (1962)

TNTIL ten or fifteen years ago1 knowledge of red cell production was based primarily on morphologic observation. During the past decade, however, the introduction and availability of isotopic technics, particularly those permitting labeling of deoxyribonucleic acid (DNA) and hemoglobin, have permitted the rapid accumulation of more quantitative information on the kinetics of red-cell production. At about the same time the work of Reissmann1 renewed interest in the regulation of erythropoiesis, culminating in Erslev's2 demonstration in anemic animals of a humoral substance that stimulates red-cell production. The existence of this plasma factor, erythropoietin, has been confirmed in a number of laboratories . . .